Amneal Pharma recalling three lots of urinary tract infection tablets in U.S.
Amneal Pharmaceutical is recalling three lots of urinary tract infection drug Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg in the U.S. due to microbial contamination.
The recall is to the consumer level as the tablets may exhibit black spots on the tablet surface due to microbial contamination. The observance of black spots was reported in a product quality complaint, U.S. Food and Drug Administration said on the nationwide recall announcement of Amneal Pharmaceutical LLC.
Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg is packaged in 100 tablet count and 500 tablet count bottles. The recall pertains only to the 400 mg/80 mg strength and the three lots. Amneal Pharmaceuticals has received no reports of adverse events, illnesses or injuries related to this recall, the U.S. FDA said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 days ago
- The Hindu
Amneal Pharma recalling three lots of urinary tract infection tablets in U.S.
Amneal Pharmaceutical is recalling three lots of urinary tract infection drug Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg in the U.S. due to microbial contamination. The recall is to the consumer level as the tablets may exhibit black spots on the tablet surface due to microbial contamination. The observance of black spots was reported in a product quality complaint, U.S. Food and Drug Administration said on the nationwide recall announcement of Amneal Pharmaceutical LLC. Sulfamethoxazole/Trimethoprim Tablets, USP, 400 mg/80 mg is packaged in 100 tablet count and 500 tablet count bottles. The recall pertains only to the 400 mg/80 mg strength and the three lots. Amneal Pharmaceuticals has received no reports of adverse events, illnesses or injuries related to this recall, the U.S. FDA said.
The Hindu
3 days ago
- The Hindu
Gland Pharma gets U.S. FDA nod for Angiotensin II Acetate Injection
Generic injectable focused Gland Pharma's version of La Jolla Pharma's Giapreza injection for increasing blood pressure in adults with septic or other distributive shock has received U.S. Food and Drug Administration approval. It is the exclusive first-to-file and consequently eligible for 180 days of generic drug exclusivity, Gland Pharma said on Wednesday, announcing U.S. FDA approval for its abbreviated new drug application related to Angiotensin II Acetate Injection 2.5 mg/mL. Bioequivalent and therapeutically equivalent to reference listed drug Giapreza of La Jolla Pharma LLC, the product had U.S. sales of around $58 million for the 12 months ended March 2025, Gland Pharma said citing IQVIA numbers. The company's shares closed 1.88% higher at ₹1,623.70 apiece on the BSE.
Time of India
5 days ago
- Time of India
US FDA launches AI tool to reduce time taken for scientific reviews
Bengaluru: The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool , Elsa , aimed at improving efficiency across its operations, including scientific reviews . "Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers," said FDA Commissioner Marty Makary. The agency said it is already using Elsa to expedite clinical protocol reviews , shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets. Once the FDA receives an application for a potential drug approval , it has six to 10 months to make a decision. Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts. "Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff," the FDA said. In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
